Skip to Content

Zygel Approval Status

FDA Approved: No
Brand name: Zygel
Generic name: cannabidiol
Dosage form: Gel
Company: Zynerba Pharmaceuticals, Inc.
Treatment for: Behavioral Symptoms associated with Fragile X Syndrome

Zygel (cannabidiol gel) is a transdermal gel formulation of cannabidiol (CBD) in development for the treatment of behavioral symptoms associated with Fragile X Syndrome (FXS).

Development Status and FDA Approval Process for Zygel

DateArticle
May  6, 2019Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)
Aug  7, 2017Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide